Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · IEX Real-Time Price · USD
1.470
+0.060 (4.26%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
184.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 430.55M |
Puma Biotechnology | 226.63M |
Rigel Pharmaceuticals | 120.35M |
Lifecore Biomedical | 103.27M |
Personalis | 74.15M |
MediWound | 19.85M |
Sangamo Therapeutics | 18.76M |
Lineage Cell Therapeutics | 8.00M |
ATOS News
- 4 days ago - Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer - GlobeNewsWire
- 24 days ago - Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer - GlobeNewsWire
- 5 weeks ago - Atossa Set to Join Russell 3000® Index Effective June 28, 2024 - GlobeNewsWire
- 7 weeks ago - Atossa to Present at the Sidoti Small-Cap Investor Conference - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire